Compare Costco Wholesale Corporation (COST) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs TransMedics Group Inc — how do they compare? Costco Wholesale Corporation trades at $946.4 (market cap $420.05B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: Costco Wholesale Corporation is far larger — about 153.3× TransMedics Group Inc's market cap, and Costco Wholesale Corporation pays a 0.62% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Costco Wholesale Corporation for 133 Days and TransMedics Group Inc for 24 Days on average.
| COST | TMDX | |
|---|---|---|
Market Cap | $420.05B | $2.74B |
Volume | 2,087,565 | 949,331 |
Sector | Consumer Staples | Health |
52-Week High | $1.09K | $150.42 |
52-Week Low | $849.63 | $61.99 |
Typical Hold Time | 133 Days | 24 Days |
Enterprise Value | $407.33B | $3.13B |
Dividend Yield | 0.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COST trades at $946.92, up 0.5% today, near its pivot point of $947. The stock shows a bullish technical trend with strong moving averages, though oscillators indicate overbought conditions. Fundamentally, revenue grew to $275.24B in 2025 with a net income margin of 3.04%, while the P/E ratio of 45.66 reflects a premium valuation. Recent news highlights strong March sales growth of 11.3% year-over-year and a membership fee increase, signaling pricing power.
The outlook remains positive with analyst consensus strongly favoring Buy (66.1%) and a price target of $1,100, implying ~16% upside. Key risks include high valuation sensitivity and competitive pressures. Earnings growth and membership renewal rates are critical catalysts for sustained appreciation, but any miss could trigger a pullback.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
